Valoe Corporation: Disclosure Under Chapter 9, Section 10 Of The Securities Market Act
| % of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | under 5 % | 0 % | under 5 % |
| Position of previous notification (if applicable) | 7,00 % | 0 % | 7,00 % |
Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights:
| Class/Type of shares ISIN code | Number of shares and voting rights | Number of shares and voting rights | % of shares and voting rights | % of shares and voting rights |
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009006951 | 29,298,067 | 0 | under 5 % | 0 % |
| A TOTAL | 29,298,067 | 0 | under 5 % | 0 % |
In Mikkeli 27 October 2023
Valoe Corporation
Board of Directors
For more information: Iikka Savisalo
President and CEO, Valoe Corporation
Tel. +358 40 521 6082, email:
Distribution:
NASDAQ OMX, Helsinki
Main media
Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides PV technology based on its own back contact technology and related projects, project design and technology consulting. Valoe also provides manufacturing technology for PV modules, module manufacturing lines, modules and key components for modules, as well as IBC solar cells manufactured at the Company's factory in Lithuania. Valoe is headquartered in Mikkeli, Finland, with production facilities in Juva, Finland, and Vilnius, Lithuania.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment